Cell culture is an important tool in life science research for finding the cause and therapies for the various chronic diseases. According to the study done, it was found that the most common cause of the disease was abnormal metabolic pathways and signaling mechanisms which are very difficult to detect.
The animal based diagnosis uses diagnosis of the disease using live animals starting from invertebrates till vertebrates. The researchers treat the animals with various drugs to get the solution in the form of therapies. However, the animal ethical committee put forth some rules and regulations in handling the number of animals, and the use of treatment on animals. The major risk in using animals for diagnosis is that the presence of disease to animal itself increases the chances of spoiling the entire experiment. This also leads to extend the time for particular experiment which simultaneously raises the cost of an experiment. It is very difficult to maintain the nutritional and physiological aspects of experimental animals. This might increase the operational cost as well. In addition, the use of animals for toxicity testing, drug screening & development, and other applications is unavoidably unpleasant and often cause discomfort. The chances of cross contamination are more in animal based diagnosis as it spreads communicable diseases. It is not always feasible to detect the internal mechanism using live animals. Thus, researchers are giving major focus on cell based diagnosis instead of animal based diagnosis.
Cell based diagnosis is primarily based on the principle that cells are grown in artificial environmental conditions using cell culture products such as media, sera, and reagents. This cell based diagnosis uses in vitro laboratory conditions and hence reduces discomfort. In addition, there are no limitations in using number of live cells as millions of cells can be isolated from less amount of specimen. It also resembles in terms of pathophysiology and metabolic pathways with in vivo conditions which reduces the experimental cost and time. In addition, the effect of toxic substances can be easily traced out using viable cells which is not possible using live animals. The cells can be easily manipulated using various molecular and cellular techniques along with specific micro environment. This directly detects the presence of genetic and chromosomal abnormalities. Also, cell based diagnosis currently uses prenatal and preimplantation genetic diagnosis as researchers uses fetal cells. This makes it easy to diagnose the disease at an early stage. Hence, cell based diagnosis plays an important role in detecting cause and treatment of diseases.
The major companies providing cell based diagnostic products in the global market are Irvine Scientific, HiMedia Laboratories, Cell Culture Company (CCC), LLC, Merck & Co., Incorporation, General Electric Healthcare (GE Healthcare), Agilent Technologies, Thermo Fisher Scientific, PromoCell GmbH, Lonza, Corning Incorporation, Becton Dickinson (BD), CellGenix GmbH, InVivo Gen, Sera Care Life Sciences, and American Type Culture Collection (ATCC).
Thus, owing to the unique properties and increasing applications in various products, cell based diagnosis has been witnessing a rapid growth in the cell culture market, which is expected to grow at a CAGR of 10.7% to reach USD 21,058 million by 2022, according to the Meticulous Research™.